

Amendment to the Specification:

At page 1, line 3, insert the following paragraph.

Cross-Reference to Related Applications

This application is a continuation-in-part of U.S. application serial no. 09/142,305, filed September 10, 1999, which, in turn, is the U.S national stage application of international application no. PCT/JP97/00687, filed March 5, 1997, which claims the benefit of Japanese application no. JP 8/47796, filed March 5, 1996.

Replace the paragraph beginning at page 4, line 4, with the following paragraph.

Furthermore, the present inventors have constructed a mutant receptor (TmR) which specifically binds to 4-hydroxytamoxifen (Tm), and have replaced the above-mentioned estrogen receptor with the TmR, to overcome influences of the endogenous estrogen on this system. Thus, the present inventors have developed the system in which gene-modified hematopoietic stem cells selectively expanded as a result that G-CSF receptor of the chimeric fusion protein is activated by stimulation of exogenous Tm without the influences of the endogenous estrogen.